Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Heijn

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Tijdschrift Voor Diergeneeskunde|September 1, 1992
[Conjunctivitis in rabbits]A Heijn
Tijdschrift Voor Diergeneeskunde|March 1, 1990
[Lens extraction]A Heijn
Tijdschrift Voor Diergeneeskunde|May 11, 2007
[Sent in by A. Heijn]A Heijn
Tijdschrift Voor Diergeneeskunde|May 15, 1997
[Sulfa..., be aware of sicca!]A Heijn
Cancer Immunology, Immunotherapy : CII|January 1, 1994
Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAbR A Janssen, A A Heijn, T H The, et al.
Transplantation|March 1, 1991
Morphologic activation of lymphocytes in blood during rejection of heart and lung grafts in ratsA L Westra, A A Heijn, T Uyama, et al.
Tijdschrift Voor Diergeneeskunde|September 1, 1992
[Be wise--refer! Fact or fantasy?]P H Poll, A Heijn, F C Stades, et al.
British Journal of Cancer|December 1, 1992
Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinomaR A Janssen, D T Sleijfer, A A Heijn, et al.
British Journal of Cancer|May 1, 1993
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with responseA Martens, R A Janssen, D T Sleijfer, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patientsR A Janssen, J Buter, E Straatsma, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Tijdschrift Voor Diergeneeskunde|September 1, 1992
[Conjunctivitis in rabbits]A Heijn
Tijdschrift Voor Diergeneeskunde|March 1, 1990
[Lens extraction]A Heijn
Tijdschrift Voor Diergeneeskunde|May 11, 2007
[Sent in by A. Heijn]A Heijn
Tijdschrift Voor Diergeneeskunde|May 15, 1997
[Sulfa..., be aware of sicca!]A Heijn
Cancer Immunology, Immunotherapy : CII|January 1, 1994
Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAbR A Janssen, A A Heijn, T H The, et al.
Transplantation|March 1, 1991
Morphologic activation of lymphocytes in blood during rejection of heart and lung grafts in ratsA L Westra, A A Heijn, T Uyama, et al.
Tijdschrift Voor Diergeneeskunde|September 1, 1992
[Be wise--refer! Fact or fantasy?]P H Poll, A Heijn, F C Stades, et al.
British Journal of Cancer|December 1, 1992
Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinomaR A Janssen, D T Sleijfer, A A Heijn, et al.
British Journal of Cancer|May 1, 1993
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with responseA Martens, R A Janssen, D T Sleijfer, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patientsR A Janssen, J Buter, E Straatsma, et al.
Pageof 2